Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sumgen Mab (Beijing) Biotech Co. Ltd. operates in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are handled by 2 distinct examiners. This distribution prevents a concentration of workload on 1 individual, which can be beneficial for managing different technical aspects of the portfolio.
The current prosecution activity is contained within 1 distinct art unit. AEDER, SEAN E is identified as the busiest examiner, overseeing 1 pending office action. This structure shows that while the technical focus is narrow within 1 art unit, the administrative load is shared between 2 examiners. For a practitioner, this means that the prosecution strategy must account for the specific tendencies of 2 different examiners even though they are working within the same technical division. The presence of 2 pending actions across 2 examiners suggests a diversified approach to 1 technical area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570792 | BISPECIFIC FUSION PROTEIN | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18176972 | CD38 PROTEIN ANTIBODY AND APPLICATION THEREOF | WEIDNER, ADAM M | 38d overdue |
| 18570792 | BISPECIFIC FUSION PROTEIN | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570792 | BISPECIFIC FUSION PROTEIN | AEDER, SEAN E | — | §102§103 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18176972 | CD38 PROTEIN ANTIBODY AND APPLICATION THEREOF | WEIDNER, ADAM M | 1675 | §112DP | Non-Final OA | 38d overdue | Pending | Mar 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial